The U.S. Food and Drug Administration (FDA) has announced that the supply shortages of Eli Lilly's (LLY, Financial) popular weight-loss and diabetes medications, Zepbound and Mounjaro, have been resolved. This resolution may impact the market presence of generic versions that had become popular due to previous shortages. The initial shortage led the FDA to permit pharmacies to sell less-tested generic versions. Eli Lilly has been increasing investments to boost medication supply, including constructing a ne ...